Kinevant Sciences, a wholly-owned subsidiary of Roivant, is focused on developing new therapies for rare auto-immune diseases, initially targeting sarcoidosis with an anti-GM-CSF monoclonal antibody (namilumab). The Company will initiate a clinical trial in pulmonary sarcoidosis in H1 2022. Sarcoidosis is a multi-organ autoimmune disease with poor treatment options that affects up to 200,000 people in the U.S. The long-term vision for Kinevant is to successfully develop and commercialize namilumab for sarcoidosis as well as develop a portfolio of candidates for other auto-immune or inflammatory orphan diseases.

Roivant’s mission is to systematically reduce the time, cost, and risk of delivering new medicines to market by accelerating the development of promising drug candidates to improve the lives of patients and their families. Since its inception in 2014 Roivant has achieved the following critical milestones: launched over 20 portfolio companies (Vants); 5 successful IPOs; $3B partnership with global pharma; pipeline of over 40 assets across various modalities and therapeutic areas; 8 successful phase 3 readouts since 2019. Traditionally, Roivant provides all the capital required for Vant operations until the Vant becomes a public company. Roivant attracts, retains, and motivates entrepreneurial company builders that have deep domain expertise with competitive compensation and benefits, including stock option grants in the Vant.

Job Summary:

The Head of Immunology Research will establish and lead the nonclinical and translational research department for the company.  In the short term this will encompass the in vitro and in vivo research strategy to further the mechanistic understanding of the role of namilumab in sarcoidosis, create the research substrate on which to base future clinical development decisions for novel indications, and identify additional promising candidates.  The Head of Immunology Research will also play a key role in identifying and evaluating new candidates in auto-immune diseases to continue to expand our pipeline. 

What You'll Do:

  • Be the Company’s in-house expert on the role of dysregulated GM-CSF biology in auto-immune and -inflammatory diseases
  • Lead development programs from the nonclinical and translational perspective by articulating a deep understanding of the underlying immunobiology and lead the development of a research agenda for Kinevant
  • Lead the development, conduct, analyses, and reporting of appropriate research studies that further the understanding of the role of namilumab in sarcoidosis
  • Lead the development, conduct, analyses, and reporting of appropriate research studies that further the understanding of the role of GM-CSF in potential future indications
  • Partner with Nonclinical, Toxicology, Clinical and other stakeholders on the design and conduct of the namilumab development plan including translational, bio-analytical, and clinical plans
  • Work closely with other functions to support programs in active development toward value inflection points (i.e. FIH, POC, BLA, registration) at Kinevant
  • Author/review relevant subsections of regulatory documents and interact with regulatory authorities
  • Provide oversight to external consultants as needed
  • Be responsible for presentations at scientific conferences and publication of the Company’s research

Who You Are:

  • PhD in relevant biological sciences (Immunology related field)
  • 10+ years experience in discovery and development
  • Excellent understanding of relevant disease models and demonstrated expertise in immunological mechanisms of action is a plus
  • Integrated understanding of drug development and the role of having an integrated scientific research plan within the broader pharmaceutical development landscape for namilumab. Prior experience on programs that led to successful IND opening trials, pivotal trials, registration, or post-marketing studies preferred
  • Excellent written and oral communication skills
  • Proven ability to independently manage multiple projects/tasks
  • Ability to travel to CRO partners (as dictated by specific study needs) on an as-needed basis 

Apply for this Job

* Required
  
  


Voluntary Self-Identification

For government reporting purposes, we ask candidates to respond to the below self-identification survey. Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiring process or thereafter. Any information that you do provide will be recorded and maintained in a confidential file.

As set forth in Kinevant Sciences’s Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law.

Race & Ethnicity Definitions

If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection. As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measure the effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categories is as follows:

A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.

A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.

An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.

An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.


Form CC-305

OMB Control Number 1250-0005

Expires 05/31/2023

Voluntary Self-Identification of Disability

Why are you being asked to complete this form?

We are a federal contractor or subcontractor required by law to provide equal employment opportunity to qualified people with disabilities. We are also required to measure our progress toward having at least 7% of our workforce be individuals with disabilities. To do this, we must ask applicants and employees if they have a disability or have ever had a disability. Because a person may become disabled at any time, we ask all of our employees to update their information at least every five years.

Identifying yourself as an individual with a disability is voluntary, and we hope that you will choose to do so. Your answer will be maintained confidentially and not be seen by selecting officials or anyone else involved in making personnel decisions. Completing the form will not negatively impact you in any way, regardless of whether you have self-identified in the past. For more information about this form or the equal employment obligations of federal contractors under Section 503 of the Rehabilitation Act, visit the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp.

How do you know if you have a disability?

You are considered to have a disability if you have a physical or mental impairment or medical condition that substantially limits a major life activity, or if you have a history or record of such an impairment or medical condition.

Disabilities include, but are not limited to:

  • Autism
  • Autoimmune disorder, for example, lupus, fibromyalgia, rheumatoid arthritis, or HIV/AIDS
  • Blind or low vision
  • Cancer
  • Cardiovascular or heart disease
  • Celiac disease
  • Cerebral palsy
  • Deaf or hard of hearing
  • Depression or anxiety
  • Diabetes
  • Epilepsy
  • Gastrointestinal disorders, for example, Crohn's Disease, or irritable bowel syndrome
  • Intellectual disability
  • Missing limbs or partially missing limbs
  • Nervous system condition for example, migraine headaches, Parkinson’s disease, or Multiple sclerosis (MS)
  • Psychiatric condition, for example, bipolar disorder, schizophrenia, PTSD, or major depression

1Section 503 of the Rehabilitation Act of 1973, as amended. For more information about this form or the equal employment obligations of Federal contractors, visit the U.S. Department of Labor's Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp.

PUBLIC BURDEN STATEMENT: According to the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless such collection displays a valid OMB control number. This survey should take about 5 minutes to complete.